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very low costs or even no medical attention, and therefore were not taken into account. 
Data sources included the published incidence rates for the 25 most frequent AE in 
controlled clinical trials with BEV + IFN or sunitinib. a panel integrated by 10 local 
experts from different specialties was constituted to estimate medical and nonmedical 
resource use for diagnosis and treatment of each AE grade 3/4. Cost of medications 
involved in treating AE were taken from public bids and unit cost of medical services 
(outpatient medical consultations, laboratory and image tests, hospitalization at 
general ward and at intensive care unit, surgical and nonsurgical procedures, etc.) was 
gathered from ofﬁ cial tariff lists. All costs are expressed in 2009 Mexican pesos 
(MXN). RESULTS: The average cost per patient for the management of grade 3/4 AE 
were 76.5% higher for sunitinib ($17,577) than those for BEV + IFN ($9959). The 
main cost drivers for sunitinib were hypertension, heart failure, and non-febrile neu-
tropenia; for BEV + IFN, main cost drivers included proteinuria and arterial and 
venous thromboembolic events. CONCLUSIONS: BEV + IFN has a more tolerable 
AE proﬁ le when compared to sunitinib, which is also reﬂ ected in the nearly double 
cost for managing AE with sunitinib in patients with mRCC.
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OBJECTIVES: First-line chemotherapy for locally advanced or metastatic non-small 
cell lung cancer (mNSCLC) is usually limited to four to six cycles, as prolonged 
exposure leads to cumulative toxicity without additional survival beneﬁ t. Maintenance 
therapy represents a new treatment option which can delay disease progression and 
extend survival in patients with mNSCLC. Erlotinib and pemetrexed are currently the 
only treatments speciﬁ cally approved for this indication by the European Medicines 
Agency and US Food and Drug Administration; therefore, it is important to compare 
the monthly treatment costs of using erlotinib or pemetrexed for the maintenance 
therapy of patients with mNSCLC. METHODS: Italian monthly treatment costs were 
calculated as the sum of the ex-factory costs for the average dose (erlotinib = 150 mg/
day, pemetrexed = 500 mg/m2) over a 30-day treatment duration plus administration 
costs. Monthly administration costs were derived from regional tariffs for oncology 
drugs. RESULTS: Monthly drug costs for erlotinib maintenance therapy are lower 
than for pemetrexed (c1517 vs. c2770, respectively). In addition, as an intravenous 
treatment, pemetrexed is associated with additional costs related to administration 
(estimated at c140 per month), whereas orally administered erlotinib is not associated 
with any administration costs. Pemetrexed total monthly treatment costs are therefore 
c2910, c1393 higher than erlotinib total monthly treatment costs. The cost saving 
associated with erlotinib would allow approximately 92% more patients to be treated 
with erlotinib maintenance therapy, based on a ﬁ xed health-care budget. Furthermore, 
it is anticipated that the management of pemetrexed-related adverse events (e.g., 
neutropenia, anaemia) would be more costly than those related to erlotinib use (e.g., 
rash, pruritus). Therefore, the cost saving when using erlotinib versus pemetrexed for 
ﬁ rst-line maintenance therapy may be greater in a real-world setting. CONCLU-
SIONS: Based on Italian costs, erlotinib is a cost-saving treatment option compared 
with pemetrexed, for the ﬁ rst-line maintenance therapy of patients with locally 
advanced or mNSCLC.
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OBJECTIVES: First-line chemotherapy for locally advanced or metastatic non-small 
cell lung cancer (mNSCLC) is usually limited to four to six cycles, as prolonged 
exposure leads to cumulative toxicity without additional survival beneﬁ t. Maintenance 
therapy represents a new treatment option which can delay disease progression and 
extend survival in patients with mNSCLC. Erlotinib and pemetrexed are currently the 
only treatments speciﬁ cally approved for this indication by the European Medicines 
Agency and US Food and Drug Administration; therefore, it is important to compare 
the monthly treatment costs of using erlotinib or pemetrexed for the maintenance 
therapy of patients with mNSCLC. METHODS: Spanish monthly treatment costs 
were calculated as the sum of the ex-factory costs for the average dose (erlotinib = 
150 mg/day, pemetrexed = 500 mg/m2) over a 30-day treatment duration plus admin-
istration costs. Monthly administration costs were obtained from regional tariffs 
(Galician Health Service). RESULTS: Monthly drug costs for erlotinib maintenance 
therapy are lower than for pemetrexed (c2045 vs. c2914, respectively). In addition, 
as an intravenous treatment, pemetrexed is associated with additional costs related to 
administration (estimated at c235 per month), whereas orally administered erlotinib 
is not associated with any administration costs. Pemetrexed total monthly treatment 
costs are therefore c3149, c1104 higher than erlotinib total monthly treatment costs. 
The cost saving associated with erlotinib would allow approximately 54% more 
patients to be treated with erlotinib maintenance therapy, based on a ﬁ xed health-care 
budget. Furthermore, it is anticipated that the management of pemetrexed-related 
adverse events (e.g., neutropenia, anaemia) would be more costly than those related 
to erlotinib use (e.g., rash, pruritus). Therefore, the cost saving when using erlotinib 
versus pemetrexed for ﬁ rst-line maintenance therapy may be greater in a real-world 
setting. CONCLUSIONS: Based on Spanish costs, erlotinib is a cost-saving treatment 
option compared with pemetrexed, for the ﬁ rst-line maintenance therapy of patients 
with locally advanced or mNSCLC.
PCN45
DIFFERENCES IN HEALTH-CARE COSTS FOR PATIENTS WITH 
CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED BY 
ONCOLOGISTS OR UROLOGISTS
Engel-Nitz NM1, Alemayehu B2, Nathan F2, Parry D3, Kulakodlu M1
1i3 Innovus, Eden Prairie, MN, USA; 2AstraZeneca, Wilmington, DE, USA; 3AstraZeneca, 
Macclesﬁ eld, Cheshire, UK
OBJECTIVES: Patients with CRPC may be treated by urologists or oncologists. This 
study examined differences in total health-care costs and prostate cancer-speciﬁ c costs 
in patients treated by oncologists or urologists. METHODS: A retrospective study 
design used medical and pharmacy claims (2001–2007) to identify patients with CRPC 
from a large US-managed care health plan. Patients were stratiﬁ ed based on the spe-
cialist providing treatment following castration; an oncologist (with/without a urolo-
gist, ONC), and a urologist without an oncologist (URO). A 6-month baseline period 
was used to assess patient characteristics and initial clinical status; a variable follow-up 
period (until disenrollment or December 31, 2008) was used to assess total health-care 
costs. Lin’s regression was used to assess costs adjusting for the variable follow-up 
and patient and treatment characteristics. RESULTS: A total of 995 URO and 1590 
ONC patients with CRPC were identiﬁ ed. Mean age was higher in URO patients than 
in ONC patients (75.5 vs. 71.1 years, P < 0.001). The URO cohort had a lower average 
Charlson comorbidity score (3.7 vs. 4.9, P < 0.001), fewer comorbid illnesses (10.1 vs. 
11.1, P < 0.001), and were less likely to have other cancers (17.7% vs. 27.4%, P < 
0.001) or to have had hormones, chemotherapy, and radiation treatment during the 
baseline period. After multivariate adjustment, mean total health-care costs during the 
ﬁ rst year were $31,792 (URO), $54,306 (ONC with chemotherapy, P < 0.05), and 
$30,894 (ONC without chemotherapy); during 6 years of follow-up, cumulative costs 
rose to $86,706 (URO), $168,794 (ONC with chemotherapy), and $114,180 (ONC 
without chemotherapy), P < 0.05 for all. a similar pattern was observed for prostate 
cancer-speciﬁ c cumulative costs. CONCLUSIONS: CRPC patients treated by oncolo-
gists, particularly patients with chemotherapy, had higher total and prostate cancer-
related health-care costs than patients treated by urologists.
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OBJECTIVES: Oncotype DX® is a clinically validated assay used to guide chemo-
therapy decision-making for patients with early-stage breast cancer. Patients classiﬁ ed 
as low risk by Oncotype DX® have low likelihood of beneﬁ tting from chemotherapy. 
By foregoing chemotherapy, patients avoid the risk of chemotherapy-related toxicities. 
For those patients reclassiﬁ ed by Oncotype DX® as high risk, the assay identiﬁ es 
patients who are likely to gain a large beneﬁ t from chemotherapy. The study objective 
was to estimate the health-care costs of using Oncotype DX® testing in early-stage, 
lymph node-negative breast cancer in Ireland. METHODS: A cost-analysis estimated 
the health-care costs (chemotherapy, administration, adverse events [AEs], and G-CSF 
costs) in patients whose treatment decisions are informed by Oncotype DX® testing. 
The perspective was that of the Irish health-care system. The chemotherapy regimen 
was docetaxel and cyclophosphamide (4 × 21-day cycles), costing approximately 
c9200. Univariate sensitivity analysis was performed, together with a probabilistic 
sensitivity analysis (PSA) of the net reduction in chemotherapy usage from Oncotype 
DX® testing. In a meta-analysis of seven published studies, there was an estimated 
30% (95% CI −40%, −21%; P = 0.0003) absolute reduction in chemotherapy usage 
after Oncotype DX® testing (ratio 0.49 [95% CI 0.41, 0.58]; P < 0.00001). RESULTS: 
Adoption of Oncotype DX® testing resulted in approximate cost-neutrality (0.4% 
increase in cost) to the Irish health-care system, under the above conditions. The main 
cost drivers were: net reduction in chemotherapy usage from Oncotype DX® testing 
and the rate of G-CSF usage. From the PSA, the probability of Oncotype DX® being 
cost-saving is approximately 47%. CONCLUSIONS: Using Oncotype DX® to inform 
chemotherapy decisions in early-stage breast cancer has the potential to reduce the 
incidence of chemotherapy-induced AEs, while being approximately cost-neutral to 
the Irish health-care system. a cost-effectiveness analysis would be expected to result 
in a low incremental cost-effectiveness ratio.
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OBJECTIVES: To describe changes in outcomes, treatment patterns and costs of the 
management of hospitalized patients with acute AML after chemotherapy in Germany 
A260 13th Euro Abstracts
over a 3-year time horizon, with a special focus on prophylaxis and treatment of 
invasive fungal infections (IFI). METHODS: This was a retrospective, single-center 
study on AML patients hospitalized for chemotherapy, neutropenia, and infections 
after myelosuppressive chemotherapy from January 2004 to December 2006. Data on 
occurrence of IFI, treatment patterns, and resource utilization were collected by chart 
review. Direct medical costs were calculated from hospital provider perspective. 
RESULTS: In total, 471 hospitalization episodes in 212 patients were eligible for 
analysis. Occurrence of IFI decreased from 5.9% in 2004 to 1.9% in 2006. Mean 
hospital stay decreased from 28.7 ± 17.9 days (2004) to 22.4 ± 11.8 days (2006) (P 
< 0.05). From 2004 to 2006, use of a single antifungal drug increased from 30.4% 
to 46.9% of episodes, whereas use of multiple antifungal drugs decreased from 24.4% 
to 13.1%. Single antifungal drug use was dominated by azoles and increased from 
23.7% (2004) to 43.4% of episodes (2006). Posaconzole monotherapy was applied 
in 26.7% of episodes. Use of liposomal amphotericin B declined from 21.4% to 3.8%, 
caspofungin from 19.3% to 8.1%, ﬂ uconazole from 25.2% to 11.9%, and voricon-
azole from 31.9% to 15.0%. Total costs per episode declined from c19,051 ± 19,024 
(2004) to c13,531 ± 9,260 (2006) (P < 0.05); main reduction was observed for anti-
mycotics, blood products, and hospital stay. CONCLUSIONS: These real-life data 
from a university hospital in Germany indicate that the antifungal management of 
AML patient hospitalized for chemotherapy, neutropenia, and infections after chemo-
therapy changed between 2004/5 and 2006. This change was accompanied by a 
decline in treatment costs. Results suggest that the introduction of posaconazole 
prophylaxis in 2006 has not only reduced the use of antifungal therapies but also the 
need for treatment with multiple antifungal drugs.
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Prostate cancer is the most common form of cancer in UK men and incidence is on 
the rise, primarily driven by increased screening. Low-risk prostate cancer has disease-
speciﬁ c survival consistently over 95%. Consequently, the UK has deemed radical 
treatments (RTs) comprising radical prostatectomy, radiotherapy, and brachytherapy 
as unnecessary for low-risk prostate cancer and recommends active surveillance (AS). 
AS does not address the disutility for patients living with cancer and in real-life over 
50% of patients proceed to RT. Alternative “focal therapies” for this patient popula-
tion are therefore generating interest. OBJECTIVES: Determine the cost-effectiveness 
of AS in the UK as practiced and contrast with focal therapy. METHODS: A Markov 
model was used to evaluate the cost-utility of treatments for low-risk prostate cancer. 
Input parameters for progression rates, efﬁ cacy, and side effects were derived from 
the literature. Biochemical and histological progression to RT plus patient choice were 
modeled. Hormonal treatment was included as salvage therapy. Age-related mortality 
rates were applied throughout the model. For focal therapy, all low-risk patients 
received treatment. Failure of treatment led to patients commencing AS, while bio-
chemical progression at any time led to RT. Costs were taken from the UK NHS 
perspective. RESULTS: Over 25 years, AS delivered 13.3 QALYs (3.5% discount rate 
applied). The QALY value was heavily weighted by the utility of 0.84 associated with 
AS. Focal therapy delivered improved QALYs (14.6) over the same period and could 
be delivered for cost parity with AS. Cost-effectiveness is discussed. CONCLUSIONS: 
UK guidelines recommend AS for low-risk prostate cancer but do not meet the needs 
of patients, evinced by low QoL and by many patients choosing RT. Hence, AS has 
“hidden costs” in the UK system and there is a place for alternative treatment 
approaches such as focal therapies.
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OBJECTIVES: To assess cancer-related costs and related predictors among elderly 
breast cancer patients in the United States. METHODS: A retrospective study was 
conducted in subjects aged ≥65 years and diagnosed with breast cancer between 
January 1, 2000 and December 31, 2005. Patients were identiﬁ ed from the SEER-
Medicare linked database that combines clinical information on cancer cases with 
longitudinal (1991–2006) Medicare claims. An index date was deﬁ ned as the date of 
the ﬁ rst observed breast cancer diagnosis. Costs (2009 US$) were aggregated from 
subjects’ index date until death, Medicare disenrollment, or database end (December 
31, 2006) and included breast cancer-related surgery, radiotherapy, chemotherapy, 
and other medical encounters carrying a breast cancer diagnosis. Generalized linear 
models with a log link function and gamma distribution were used to assess predictors 
of costs. Age, race, stage at diagnosis, hormone receptor status (ER/PR), nodal status, 
Charlson comorbidity score, and chemotherapy use were key explanatory variables. 
RESULTS: The majority of the 66,217 breast cancer subjects selected were aged 70 
to 79 years (47%), Caucasian (88%), and in localized stage (67%) at diagnosis. 
Median follow-up was 50 onths. Approximately 5% of cases were diagnosed in the 
metastatic stage with a median follow-up of 26 months. Approximately 73% of 
subjects with metastatic disease died during follow-up compared to 21% of localized 
cases. Cancer-related adjusted costs per patient were $55,120 (median $25,991) for 
all cases and $153,421, $82,789, and $38,099, for metastatic, regional, and local stage 
cases, respectively. Regional and metastatic stage at diagnosis, increased age, increased 
number of cancer-positive lymph nodes, negative estrogen/progesterone receptor 
status, and chemotherapy use were found to be signiﬁ cant (P < 0.001) predictors of 
higher costs. CONCLUSIONS: Clinical characteristics indicating poorer prognosis are 
associated with signiﬁ cantly higher breast cancer costs. Patients with metastatic disease 
carry the highest cost of care despite having shorter follow-up and poorer survival.
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OBJECTIVES: Hepatocellular carcinoma (HCC) is a rapidly progressing, fatal disease. 
However, little is known regarding the hospitalization burden for these patients. This 
study compares the burden of hospitalizations due to HCC and hepatobiliary condi-
tions relative to other nonhepatobiliary comorbid conditions. METHODS: Insurance 
claims (Janaury 1, 2000—December 31, 2008) from a geographically diverse, com-
mercially insured US population were used to identify a cohort of patients with > = 1 
HCC claim (index = 1st claim), age > = 18, and no other cancer diagnoses in the year 
prior to index. Hospitalizations were grouped by primary diagnosis (ICD-9) codes 
into the following categories: 1) HCC and hepatobiliary, and 2) nonhepatobiliary. 
Hospitalization burden was compared between these categories based on: number of 
hospitalizations, time to occurrence since HCC diagnosis, length of stay, and cost 
(2009 USD). The number of hospitalizations was compared using a sign test for 
patient-level differences. The remaining parameters were compared using general 
estimating equations to adjust for patients with multiple hospitalizations. RESULTS: 
This study identiﬁ ed 2927 HCC patients (mean age 50.4 years, 57% male) and 2192 
hospitalizations. The subset of patients with > = 1 hospitalization (n = 1083, 37%) 
had an average of 2.02 admissions per patient with a median of 11.8 follow-up 
months. Compared to the nonhepatobiliary hospitalizations, the HCC and hepatobili-
ary hospitalizations had: a higher number of admissions (0.40 vs. 0.35 per patient; P 
< 0.001), a shorter time to occurrence (112 vs. 330 days; P < 0.001), a longer length 
of stay (6.4 vs. 5.4 days; P < 0.007), and a higher average cost per admission ($48,539 
vs. 23,221; P < 0.001). The total cost of HCC and hepatobiliary hospitalizations was 
2.3 times higher than nonhepatobiliary hospitalizations ($56,451,173 vs. $23,894,444). 
CONCLUSIONS: HCC and hepatobiliary conditions accounted for the majority of 
the hospitalization burden in liver cancer patients. Future HCC therapies demonstrat-
ing reduced symptom progression may reduce the prevalence, duration, and cost of 
HCC and hepatobiliary-related hospitalizations.
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OBJECTIVES: Human papillomavirus (HPV) infection is a necessary cause of cervical 
cancer and is associated with a subset of other anogenital (anal, vulvar, vaginal, penile) 
and head/neck cancers (oral cavity, oropharynx/pharynx, larynx). The overall HPV-
related disease burden is considerable in Europe. This study aimed to assess the 
hospital costs of HPV-related cancers for both genders in France. METHODS: Hos-
pitalization costs were collected from a recent publication for cervical cancer and from 
the French national hospital database (PMSI) for other cancers. Costs included hos-
pital stays, radiotherapy, and chemotherapy sessions. Annual costs for each cancer 
were estimated from the health-care payers’ perspective. RESULTS: In 2006, the 
annual costs of cervical cancer were estimated at c43.9 million. In addition, vulvar 
and vaginal cancers were associated with c9.7 million annually. For anal cancer, the 
annual costs were c20.3 million (male: c6.3 million; female: c14 million). Penile cancer 
hospitalizations represented c2.6 million annually. The estimated annual costs for 
head/neck cancers in 2007 for males and females, respectively, were c54.4 and c17.1 
million for oral cavity, c128.2 and c21.7 million for oropharynx/pharynx, and c47.8 
and c5.5 million for larynx. Considering the assumed proportion of cancers attribut-
able to HPV (cervical: 100%; vulvar: 34.7%; vaginal 76.8%; anal: 84.2%; penile: 
46.7%; oral cavity: 16.0%; oropharynx: 28.2%; larynx: 21.3%, in Europe), the 
overall hospitalization costs due to HPV-related cancers were estimated at c61.6 
million in males and c70.8 million in females. CONCLUSIONS: The hospital burden 
of HPV-associated cancers in males is almost similar as in females, in France. This 
burden is probably underestimated since outpatient and indirect costs were not 
included.
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OBJECTIVES: In our study, we estimated social and economic burden of hepatocel-
lular carcinoma (HCC) in Russian Federation resulting from HCC from the position 
of public health-care system. METHODS: All types of costs were calculated—direct 
